Tracks blood pressure problems in people with B-cell cancers taking BTK inhibitors
Observes how high blood pressure is managed in adults with B-cell cancers on BTK inhibitors.
Key facts
- Who runs it
- Mayo Clinic
- Where
- Rochester, United StatesSee the site
- Trial code
- Registry title
- Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study
- Status
- Recruiting
- People taking part
- 100 people, planned
- Started
- 5 Jan 2024
- Planned end
- 30 Jun 2026
- Type of study
- Observational
- Treatments tested
- Non-Interventional Study
- Record updated
- 27 February 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people with certain B-cell cancers who are about to start a BTK inhibitor medicine. It studies new or worse high blood pressure during treatment.
- Sex
- All sexes can join.
- Disease stage
- Chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenstrom macroglobulinemia (WM) or marginal zone lymphoma (MZL).
- Earlier treatment
- Planned to begin Bruton tyrosine kinase inhibitors (BTKi) treatment, or to start a new BTKi agent after a 5-day wash out period. It can be alone or with other chemotherapies.
Main reasons for not taking part
- Known central nervous system (CNS) involvement of the B-cell cancer
- Not willing to return to Mayo Clinic for ongoing follow-up
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- Patients with chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenstrom macroglobulinemia (WM), and marginal zone lymphoma (MZL), planned to begin Bruton tyrosine kinase inhibitors (BTKi) treatment or who will start a new BTKi agent after a 5-day wash out period (either as a single agent or on combination with other chemotherapies), who are willing to return to Mayo Clinic for ongoing follow-up
Who cannot take part
- Patients with known central nervous system (CNS) involvement of their B-cell malignancy
Where in United States
- Mayo Clinic in RochesterRochester, United StatesContact: Clinical Trials Referral OfficeTaking people
About the trial
What the trial wants to find out
This study evaluates the incidence and management of new and worsening high blood pressure in patients with B-cell cancers on BTKi treatment.
The group in the trial
- Observational
Patients attend hypertension clinic visits, undergo optional blood pressure monitoring, electrocardiograms, impedance cardiography testing and blood and urine sample collection and have medical records reviewed throughout study.
Treatment: Non-Interventional Study
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-Cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors (HALT) - A Pilot Study
- Plain-language title
- Tracks blood pressure problems in people with B-cell cancers taking BTK inhibitorsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 27 February 2026